Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Microglia Activation in Schizophrenia
NCT02932605Completed
- Start
- Nov 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in schizophrenia comparing Cannabidiol with Placebo (2 arms). Primary endpoint: Concentration of prefrontal metabolites as measured with 1H-MRS at 4 weeks. Started Nov 2017; status: completed.
02
Drugs
cannabidiol
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02932605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02932605.